6th Global Symposium on Ketogenic Therapies for Neurological Disorders

总结 生酮饮食（KD）自1921年在美国诞生以来， 明尼苏达州罗切斯特的马约诊所。当科学家们继续研究其广泛的抗惊厥作用时， 有越来越多的实验证据表明其具有改善疾病和神经保护的特性。在这 快速发展的领域，有新的机制和证据支持更广泛地使用 KD（和变体）可对抗多种神经系统疾病，包括癌症、偏头痛、自闭症和痴呆。 尽管有疗效和可负担性，但世界上大部分地区不提供KD治疗-特别是在 东南亚、东欧和非洲。有兴趣提供KD的中心可以选择不这样做 由于认为资源不足;熟悉KD的医生和/或营养师可能缺席。 此外，关于机制、应用和协议的最新研究可能没有得到很好的传播， 缺乏标准化的协议和管理建议也构成了额外的障碍。 如果没有足够的支持，患者可能不会考虑这种治疗，因为它的限制性。国际 需要召开科学家、医生、营养师、护士、社会工作者和学生可以见面的会议 并讨论KD领域的协议，研究创新，临床经验和合作。 第六届生酮治疗全球研讨会是一个成功的和不断发展的两年期系列的一部分。 第一，癫痫和其他神经系统疾病饮食疗法国际研讨会 （凤凰城，亚利桑那州，2008年），是美国国立卫生研究院的支持，并成为该系列的第一个，建立了高水平的 科学和参与随后成功的研讨会（爱丁堡，2010年;芝加哥，2012年;利物浦， 2014; Banff，2016）。它还确立了持久的合作精神和共同目标。第六 生酮疗法全球研讨会（济州岛，韩国，2018年）代表了另一个飞跃： 重点仍然是促进临床和基础科学家之间的合作互动， 学员，并传播最新的研究，以社区和超越，并强调 重点是标准化和加强国际传播和执行。到 来自世界各地的专家将分享他们的数据和经验， 将为来自资源有限地区的与会者举办教育会议， 专业的KD专家我们延续了将年轻专业人士、女性和 残疾人进入该领域，并像以前的研讨会，提供所有与会者的合作精神和动力 以进一步利用代谢疗法。为与会者参与和小组安排了充足的时间 讨论，这是以往专题讨论会的一个深受欢迎和活跃的特点。教师和主持人是 国际公认的专家和第六届全球研讨会是继续 神经系统疾病代谢疗法的进展和宣传。

SUMMARY The ketogenic diet (KD) is an established therapy for drug-resistant epilepsy since its origins in 1921 at the Mayo Clinic in Rochester, Minnesota. While scientists continue to study its broad anticonvulsant effects there is mounting experimental evidence for disease-modifying and neuroprotective properties. In this rapidly advancing field there is emerging data on mechanisms and evidence supporting broader use of the KD (and variants) against diverse neurological conditions including cancer, migraine, autism and dementia. Despite efficacy and affordability large regions of the world do not offer KD therapy – particularly in Southeast Asia, Eastern Europe and Africa. Centers interested in offering KD may elect not to do so because of perceived inadequate resources; physicians and/or dietitians familiar with KD may be absent. Furthermore, the latest research on mechanisms, applications and protocols may not be well disseminated, and a lack of standardized protocols and management recommendations present additional barriers. Without adequate support patients may not consider this treatment due to its restrictiveness. International meetings are needed where scientists, physicians, dietitians, nurses, social workers and students can meet and discuss protocols, research innovation, clinical experience and collaboration in the KD field. The Sixth Global Symposium on Ketogenic Therapies is part of a successful and evolving biennial series. The first, the International Symposium on Dietary Therapies for Epilepsy and Other Neurological Disorders (Phoenix, Arizona, 2008), was NIH-supported and became the first in the series, establishing a high level of science and participation for subsequent successful symposia (Edinburgh, 2010; Chicago, 2012; Liverpool, 2014; Banff, 2016). It also established an enduring collaborative spirit and common purpose. The Sixth Global Symposium on Ketogenic Therapies (Jeju Island, Korea, 2018) represents another leap forward: the focus remains on promoting collaborative interactions among clinical and basic scientists and trainees, and disseminating the latest research to the community and beyond, and a strong emphasis is placed on standardizing and enhancing international dissemination and implementation. To achieve the highest international impact experts from around the world will share their data and experience, and education sessions will be held for attendees from resource-limited regions with a limited number of trained KD experts. We continue the tradition of bringing young professionals, women and people with disabilities into the field, and, like previous symposia, offer all attendees a collaborative spirit and motivation to further leverage metabolic therapies. Ample time is scheduled for attendee engagement and group discussions, a well-received and robust feature of previous symposia. The faculty and moderators are internationally recognized experts and the Sixth Global Symposium is the definitive venue for continued progress in and advocacy for metabolism-based therapies for neurological disorders.